Once the new dose stabilizes and side effects subside, return to abdominal injection
Emerging Research Directions Beyond the standard protocols, researchers are exploring several innovative applications: Combination with newer agents Investigating cagrilintide paired with emerging compounds like retatrutide or other multi-receptor agonists
But for many people, the base prices are too high a barrier to consider scaling
At the 12mg dose, participants lost an average of 24.2% of their body weight in just 48 weeks
However, this comparison must be interpreted cautiously given differences in study duration, patient populations, and regulatory status
Novo Nordisk: Top Legal Representatives Novo Nordisks top legal representative was from Japan-based Sonoda & Kobayashi, followed by Murayama Yasuhiko of Shiga International Patent Office